Bellevue Group »

Arcellx shares owned by Bellevue Group

Quarter-by-quarter ownership of Arcellx (ACLX) shares owned by Bellevue Group from 13F filings

Historical chart of Bellevue Group investment in Arcellx

Tip: Access up to 7 years of quarterly data

All positions including Arcellx held by Bellevue Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arcellx by Bellevue Group

Quarter filed Position value Share count Share price at filing
2024-09-30 $334k 4.0k 83.51

More positions owned by Bellevue Group

Argenx Se Sponsored Adr (ARGX)
Ionis Pharmaceuticals (IONS)
Vertex Pharmaceuticals Incorporated (VRTX)
Intuitive Surgical Com New (ISRG)
Alnylam Pharmaceuticals (ALNY)
Revolution Medicines (RVMD)
Neurocrine Biosciences (NBIX)
Boston Scientific Corporation (BSX)
Abbott Laboratories (ABT)
Stryker Corporation (SYK)
Intra Cellular Therapies (ITCI)
Agios Pharmaceuticals (AGIO)
Incyte Corporation (INCY)
UnitedHealth (UNH)
Moderna (MRNA)

View all positions for Bellevue Group

Top funds holding Arcellx

Paradigm Biocapital Advisors
BlackRock
Perceptive Advisors
NEA Management Company
BlackRock
Sr One Capital Management
Vanguard Group
Henderson Group
T. Rowe Price Associates
RA Capital Management
State Street Corporation
Cormorant Asset Management
Suvretta Capital Management
Susquehanna International
Geode Capital Management

View all funds holding Arcellx